A genetic polymorphism of matrix metalloproteinase 9 (MMP-9) affects the changes in circulating MMP-9 levels induced by highly active antiretroviral therapy in HIV patients (2009)
- Authors:
- USP affiliated authors: GERLACH, RAQUEL FERNANDA - FORP ; MACHADO, ALCYONE ARTIOLI - FMRP ; SANTOS, JOSE EDUARDO TANUS DOS - FMRP
- Unidades: FORP; FMRP
- DOI: 10.1038/tpj.2009.13
- Subjects: POLIMORFISMO; METALOPROTEINASES; SÍNDROME DE IMUNODEFICIÊNCIA ADQUIRIDA (TERAPIA); FARMACOGENÉTICA
- Language: Inglês
- Imprenta:
- Source:
- Título: The Pharmacogenomics Journal
- ISSN: 1470-269X
- Volume/Número/Paginação/Ano: v. 9, n. 4, p. 265-273, 2009
- Este periódico é de acesso aberto
- Este artigo NÃO é de acesso aberto
-
ABNT
DEMACQ, Caroline et al. A genetic polymorphism of matrix metalloproteinase 9 (MMP-9) affects the changes in circulating MMP-9 levels induced by highly active antiretroviral therapy in HIV patients. The Pharmacogenomics Journal, v. 9, n. 4, p. 265-273, 2009Tradução . . Disponível em: https://doi.org/10.1038/tpj.2009.13. Acesso em: 14 fev. 2026. -
APA
Demacq, C., Vasconcellos, V. B., Marcaccini, A. M., Gerlach, R. F., Machado, A. A., & Santos, J. E. T. dos. (2009). A genetic polymorphism of matrix metalloproteinase 9 (MMP-9) affects the changes in circulating MMP-9 levels induced by highly active antiretroviral therapy in HIV patients. The Pharmacogenomics Journal, 9( 4), 265-273. doi:10.1038/tpj.2009.13 -
NLM
Demacq C, Vasconcellos VB, Marcaccini AM, Gerlach RF, Machado AA, Santos JET dos. A genetic polymorphism of matrix metalloproteinase 9 (MMP-9) affects the changes in circulating MMP-9 levels induced by highly active antiretroviral therapy in HIV patients [Internet]. The Pharmacogenomics Journal. 2009 ; 9( 4): 265-273.[citado 2026 fev. 14 ] Available from: https://doi.org/10.1038/tpj.2009.13 -
Vancouver
Demacq C, Vasconcellos VB, Marcaccini AM, Gerlach RF, Machado AA, Santos JET dos. A genetic polymorphism of matrix metalloproteinase 9 (MMP-9) affects the changes in circulating MMP-9 levels induced by highly active antiretroviral therapy in HIV patients [Internet]. The Pharmacogenomics Journal. 2009 ; 9( 4): 265-273.[citado 2026 fev. 14 ] Available from: https://doi.org/10.1038/tpj.2009.13 - Genetic polymorphism of matrix metalloproteinase (MMP)-9 does not affect plasma activity in healthy subjects
- Methodological issues affecting the determination of plasma matrix metalloproteinase (MMP)-2 MMP-9 activities
- Recombinant human matrix metalloproteinase-2 impairs cardiovascular 'beta'-adrenergic responses
- Circulating cell-free DNA levels in plasma increase with severity in experimental acute pulmonary thromboembolism
- The effect of sildenafil on pulmonary embolism-induced oxidative stress and pulmonary hypertension
- Sodium nitrite attenuates MMP-9 production by endothelial cells and may explain similar effects of atorvastatin
- Increased circulating levels of matrix metalloproteinase (MMP)-8, MMP-9, and pro-inflammatory markers in patients with metabolic syndrome
- Nebivolol attenuates prooxidant and profibrotic mechanisms involving TGF-β and MMPs, and decreases vascular remodeling in renovascular hypertension
- Comparative study on antioxidant effects and vascular matrix metalloproteinase-2 downregulation by dihydropyridines in renovascular hypertension
- Nitrite or sildenafil, but not BAY 41-2272, blunt acute pulmonary embolism-induced increases in circulating matrix metalloproteinase-9 and oxidative stress
Informações sobre o DOI: 10.1038/tpj.2009.13 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
